According to a recent study, home-based narrowband UV-B phototherapy for plaque and guttate psoriasis is as effective as office-based treatments.
Exclusive content available for ISSS and SSS attendees
The Indigenous Skin Spectrum Summit will be held on Friday, Oct. 4, followed by the Skin Spectrum Summit on Saturday, Oct. 5.
Veterans are more at risk for psoriasis, skin cancer
According to a recent study, U.S. veterans are more likely to have a history of skin cancer, melanoma, and psoriasis when compared to non-veterans.
Risk of pediatric AD associated with childhood obesity
According to a recent study, risk of pediatric atopic dermatitis (AD) is associated with childhood obesity and correlated to weight loss and gain.
Extended guselkumab dosing effective for PsO super responders
According to a recent study, extending the dosing interval of guselkumab from eight weeks to sixteen weeks is non-inferior for treating moderate-to-severe psoriasis in super-responders.
Cendakimab safe, efficacious in treating moderate-to-severe AD
According to a recent study, cendakimab is safe and efficacious in treating moderate-to-severe atopic dermatitis (AD) in adult patients.
PsO disease severity linked to missed work days
According to a recent study, patients with moderate-to-severe psoriasis are more than twice as likely to take a half-day off work than those with mild psoriasis.
Rosacea associated with melanoma in white patients
According to a recent study, White rosacea patients have an increased risk for malignant melanoma than non-White patients.
Study suggests significant autoimmune disease prevalence in PsO patients
According to a recent study, there is a significant autoimmune disease prevalence in psoriasis patients.
Fixed-dose, triple-combination gel efficacious, safe in moderate-to-severe acne patients
According to a recent study, a fixed-dose, triple-combination of clindamycin phosphate 1.2%, adapalene 0.15% and benzoyl peroxide 3.1% (CAB) topical formulation demonstrated efficacy and safety in both adult and pediatric patients with moderate-to-severe acne.
HealthMinute.TV 